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Abstract
Background: Epigenetic silencing of the MGMT gene by promoter methylation is associated with loss of MGMT
expression, diminished DNA-repair activity and longer overall survival in patients with glioblastoma who, in
addition to radiotherapy, received alkylating chemotherapy with carmustine or temozolomide. We describe and
validate a rapid methylation sensitive quantitative PCR assay (MS-qLNAPCR) using Locked Nucleic Acid (LNA)
modified primers and an imprinted gene as a reference.
Methods: An analysis was made of a database of 159 GBM patients followed between April 2004 and October
2008. After bisulfite treatment, methylated and unmethylated CpGs were recognized by LNA primers and molecular
beacon probes. The SNURF promoter of an imprinted gene mapped on 15q12, was used as a reference. This
approach was used because imprinted genes have a balanced copy number of methylated and unmethylated
alleles, and this feature allows an easy and a precise normalization.
Results: Concordance between already described nested MS-PCR and MS-qLNAPCR was found in 158 of 159
samples (99.4%). The MS-qLNAPCR assay showed a PCR efficiency of 102% and a sensitivity of 0.01% for LNA
modified primers, while unmodified primers revealed lower efficiency (69%) and lower sensitivity (0.1%). MGMT
promoter was found to be methylated using MS-qLNAPCR in 70 patients (44.02%), and completely unmethylated
in 89 samples (55.97%). Median overall survival was of 24 months, being 20 months and 36 months, in patients
with MGMT unmethylated and methylated, respectively. Considering MGMT methylation data provided by MS-
qLNAPCR as a binary variable, overall survival was different between patients with GBM samples harboring MGMT
promoter unmethylated and other patients with any percentage of MGMT methylation (p = 0.003). This difference
was retained using other cut off values for MGMT methylation rate (i.e. 10% and 20% of methylated allele), while
the difference was lost when 50% of MGMT methylated allele was used as cut-off.
Conclusions: We report and clinically validate an accurate, robust, and cost effective MS-qLNAPCR protocol for the
detection and quantification of methylated MGMT alleles in GBM samples. Using MS-qLNAPCR we demonstrate
that even low levels of MGMT promoter methylation have to be taken into account to predict response to
temozolomide-chemotherapy.
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Transcriptional inactivation by cytosine methylation at
promoter CpG islands of tumour suppressor genes is
thought to be an important mechanism in human carci-
nogenesis. A number of tumour suppressor genes,
including CDKN2A, MGMT, MLH1, etc, are silenced by
promoter methylation in a variety of tumors [1]. In the
course of tumor development, gene silencing by DNA
methylation is an early and important mechanism by
which tumor-suppressor genes are inactivated [2,3].
Epigenetic silencing of the MGMT gene by promoter
methylation is associated with loss of MGMT expression
[4-6], diminished DNA-repair activity and longer overall
survival in patients with glioblastoma (GBM) who, in
addition to radiotherapy, received alkylating chemother-
apy with temozolomide [7]. The MGMT gene is located
on chromosome 10q26 and encodes a DNA-repair pro-
tein that removes alkyl groups from the O
6position of
guanine, an important site of DNA alkylation. The
restoration of the DNA consumes the MGMT protein,
which the cell must replenish. Left unrepaired, che-
motherapy-induced lesions, especially O6-methylgua-
nine, trigger cytotoxicity and apoptosis [8,9]. High levels
of MGMT activity in cancer cells create a resistant phe-
notype by blunting the therapeutic effect of alkylating
agents and may be an important determinant of treat-
ment failure [3,8-13]. Patients with glioblastoma con-
taining a methylated MGMT promoter showed a major
benefit from temozolomide [14].
Given the key roles of cytosine methylation, there has
been a wide interest in the development of procedures
for DNA methylation analyses [2,3,6,15-26].
Vlassenbroeck I et al. [27] described a Real Time by
SYBRGreen method to detect MGMT methylation sta-
tus. The copy number of the methylated MGMT pro-
moter, normalized to the ACTB gene, provides a
quantitative test result. Woidacz TK et al. showed that
MGMT methylation could be detected at levels as low
as 0.1%. by high resolution melting analysis [28].
Here we present a novel methylation sensitive quanti-
tative real time PCR assay (MS-qLNAPCR) which per-
mits high throughput quantification of the methylation
status of the MGMT promoter in an accurate, very sen-
sitive and cost-effective manner. High specificity was
achieved recognizing methylated and unmethylated
CpGs by 3’-locked nucleic acid (LNA) primers and
molecular beacon probes [29]. The CpG islands of
SNURF were selected as a reference locus. SNURF
belongs to the 15q imprinted center mapped on 15q12.
The maternal allele is usually methylated, while the
paternal one is unmethylated [30]. In theory in a homo-
geneous population of cells of the same individual the
methylated maternal alleles should be balanced with the
unmethylated paternal alleles if the tumor cells did not
acquire any deletion for this locus or aberrant methyla-
tion of the paternal allele. This feature allows an easy
and precise calculation of the ratio between the methy-
lated and unmethylated alleles of MGMT following the
method described by Ginzinger et al. [31].
Methods
Tumor Samples
For this study, samples were retrieved from the Pathol-
ogy Section of the University of Bologna at Bellaria Hos-
pital (Bologna). Tumors were classified and graded
according to 2007 WHO [32] criteria. The use of brain
tumor tissue after completing histopathological diagno-
sis for research purposes was approved by the regional
ethics committee.
Following patient charts review, a retrospective analy-
sis was made of a database of GBM patients followed
prospectively between April 2004 and October 2008.
We evaluated only patients who met the following inclu-
sion criteria: age ≥ 18 years; Performance Status (PS) at
diagnosis, 0-2; histological diagnosis of newly diagnosed
GBM; MGMT methylation status assessed by methyla-
tion specific nested PCR; postoperative treatment con-
sisting of radiotherapy (RT) followed by adjuvant
temozolomide (TMZ) (14 patients) or TMZ concurrent
with and adjuvant to RT (145 patients) [7]. Twenty-four
blood samples from healthy donors were used as
controls.
DNA isolation
Tissue blocks were selected for DNA extraction after
careful examination on hematoxylin and eosin staining
of corresponding sections to exclude contaminating
necrotic debris. Molecular genetic analyses were per-
formed on samples showing an estimated tumor cell
content of at least 90% from five sections of 10 μm
from paraffin embedded tissue (FFPE) blocks. Tumor
area was macrodissected manua l l yb yas t e r i l eb l a d eo r
were microdissected using the laser assisted SL μcut
Microtest (MMI GmbH, Glattbrugg, Switzerland) as
previously described[33]. Two incubations with xylene
at 60°C and two incubations with absolute ethanol at
room temperature for ten minutes each were used to
eliminate paraffin. The tissues were then incubated with
NaSCN 1 M for one hour at 37°C and lysed with protei-
nase K at 55°C overnight. Genomic DNA was extracted
using the GENTRA Puregene tissue kit (Qiagen, Hilden,
Germany) in accordance to the manufacturer’si n s t r u c -
tions. The pellet was then eluted in 35 μlo fT Eb u f f e r
and total DNA was quantified by Quant-iT™ dsDNA BR
kit (Invitrogen, Carlsbad, California). At least 200 ng of
DNA was then treated with bisulfite using the EpiTect
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manufacturer’s instructions.
In Vitro Methylation Assay and Standards
To test for sensitivity and specificity of MS-qLNAPCR,
titration experiments were performed using normal
pooled genomic DNA (DNA Female pool, Cod. G1521,
Promega, Madison, Wisconsin) which was methylated in
vitro using SssI (New England Biolabs, Ipswich, MA). In
brief, 1.5 μg was treated with SssI to methylate all CpG
sites (near complete methylation and no loss of DNA
was assumed) for two hours at 37°C following the
instruction of the provider. Mixtures of SssI-treated
DNA: untreated DNA (100%, 50%, 10%, 1%, 0.1% 0.01%)
were prepared in duplicate (each containing 1.5 μgo f
template DNA). 50% SssI-treated DNA: untreated DNA
served as calibrator for MGMT MSP-qPCR, while the
same DNA amount of untreated DNA pool (Promega,
Madison, Wisconsin) served as calibrator for SNURF
MSP-qPCR to confirm equal amounts of maternal
methylated allele and paternal unmethylated allele. The
same DNA pool was used to test for specificity in terms
of absence of amplicons for the MGMT methylated
allele for single runs.
MS-nested PCR and MS-qLNAPCR
Nested MS-PCR was performed as previously described
[34,35] with minor modifications: a total of 26 cycles for
the flanking primers and a total of 30 cycles for the
methylation specific primers were performed. Amplicons
were detected by SeaKem LE agarose gel (3%, Lonza,
Basel, Switzerland) by the use of GelStar (Lonza, Basel,
Switzerland) as intercalator. Real Time PCR analysis was
performed using an SDS-ABI Prism 7000 (Applied Bio-
systems, Foster City, CA). 3’-locked nucleic acid (LNA)
primers (see Table 1) were synthesized by SIGMA-Pro-
ligo (SIGMA-Proligo, Paris, France). Reactions were
performed in a final volume of 25 μl, adjusted to 4 mM
of MgCl2 and containing 1 Unit of FastStartTaq DNA
Polymerase (Roche, Mannheim, Germany), 1× related
Buffer and 5 μl of 5× GC rich solution, 200 μMo f
dNTPs, 0.5 μl of ROX 50× (Invitrogen, Carlsbad, Cali-
fornia), 500 nM of each primers, 250 nM of beacon
probe and 3 μl of bisulfite treated DNA. The real time
qPCR cycling conditions were as follows: 95°C for 4
min, 60°C for 2 min, 72°C for 2 min, followed by 40
cycles for 20 s at 95°C, 45 s at 60°C with fluorescence
measurement, 30 s at 72°C.
Relative Quantification of the Methylated Allele
The number of PCR cycles (Ct)r e q u i r e df o rt h eF A M
intensities to exceed a threshold just above background
was calculated for the test (MGMT) and reference
(SNURF) reactions as described previously [31] with
some modifications: Ct values were determined for each
sample and subtracted to obtain:
Ct Ct m u Ct  m u    [] [ ( ) ] . MGMT MGMT SNURF SNURF
(mMGMT: methylated allele; uMGMT:u n m e t h y l a t e d
allele; mSNURF: methylated allele; uSNURF:u n m e t h y -
lated allele).
ΔCt values were measured for each unknown sample
[ΔCt (test DNA)] and for calibrator [ΔCt (equal amount
of SssI-treated DNA mixed with the same amount of
untreated DNA)].
Relative copy number at each locus in the test sample
was then calculated as:
Relative Methylated allele copy number = (1+E)
-ΔΔCt
where:
ΔΔCt = ΔCt (test DNA) - ΔCt (calibrator DNA), and
E = PCR efficiency. The efficiency of PCR was calculated
from the slope of the line, E = 10
-1/slope -1 .W eu s e d
primers with PCR efficiencies of >95% and We calcu-
lated the relative DNA copy number ratio respect the
Table 1 primers and beacon probes used in this study:
gene Primer forward Beacon probe Primer reverse
MGMT METHYLATED 5’-TTTCGACGTTCGTAGGTTTTCG+C-3’ 5’-FAM- CCGGAGCGTATCGTTTGCGAT-
TTGGTGAGTGTGCTCCGG-BHQ1-3’
5’-GCACTCTTCCGAAAACGAAAC+G-3’
MGMT
UNMETHYLATED
5’-TTTGTGTTTTGATGTTTGTAGGTTTTTG
+T-3’
5’-FAM-
CCGGTGCTGTATTGTTTGTGATTTG-
GTGAGTGTGCACCGG-BHQ1-3’
5’-AACTCCACACTCTTCCAAAAACAAAAC
+A-3’
SNURF METHYLATED 5’-GGATTTTTGTATTG+CGGTAAATAAGTA
+C-3’
5’-FAM-
CCGGAGGGAGGTAGGTTGGCGCGTAT-
GTTTAGCCTCCGG-BH1-3’
5’-CGCTACAACAAC+GACAAACTTC+G-3’
SNURF
UNMETHYLATED
5’-GGATTTTTGTATTG+TGGTAAATAAGTA
+T-3’
5’-FAM-
CCGGAGGGAGGTAGGTTGGTGTGTAT-
GTTTAGGCCTCCGG-BH1-3’
5’-CTCACTACAACAAC+AACAAACTTC
+A-3’
SNURF FLANKING
PRIMERS
GGGAGTT+GGGATTTTT+GTATTG CTCCC+CAAACTATCT+CTTAAAAAAAA
(LNA nucleotides are preceeded by +; CpG discriminatory LNA nucleotides are in bold)
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-ΔΔCt as
previously described [31].
A sample of 24 healthy controls was used to estimate
the normality range of the differences between methy-
lated and unmethylated SNURF alleles; the normality
range was estimated as the mean value ± 1.96 * standard
deviation.
Results were considered invalid if criteria of DNA
quantity and quality were not met. These were based on
minimal starting amplifiable DNA of approximately 6.25
ng (equivalent of ~1000 copies of a diploid human gen-
ome) available for amplification after bisulfite treatment
and calculated by ABI 7000 SDS software using the
standard curve for uMGMT. For this purpose, serial
dilutions of normal female DNA (DNA Female pool,
Cod. G1521, Promega, Milan) were tested by uMGMT
primers to create a standard curve and calculate the
starting amount of each DNA specimen. Positive signals
from uMGMT,m SNURF and uSNURF were considered
as internal controls for PCR reaction in order to exclude
the presence of PCR inhibitors. Cases below a threshold
of approximately 6.25 ng were repeated starting from a
higher amount of tumor tissue. Specimens showing a
threshold below this limit were considered invalid and
were excluded from the study. The investigators who
performed the MS-qLNAPCR tests were blinded to the
clinical data and patient outcome.
Primers and molecular beacon probes design
Previously described primers for methylated and unmethy-
lated MGMT promoter [14,19,35] were modified only to
insert LNA nucleotides at the 3’ end of their sequence
(See Table 1). Primers for SNURF were designed using
MethPrimer http://www.urogene.org/methprimer/index1.
html[36] and verified by methBlast http://medgen.ugent.
be/methBLAST (see Fig. 1 and Table 1).
Molecular beacon probes (see Table 1) were designed
using the Primer3 software http://frodo.wi.mit.edu/cgi-
bin/primer3/primer3_www.cgi including two CpG sites
each. Flanked molecular beacon arms were designed
using the OLIGO 6.0 software reaching a temperature
between 57°C and 61°C in the stem loop conformation.
LNA nucleotide were added to primers as described
previously [37] using a Tm prediction tool available at
exiqon web site http://www.exiqon.com. Amplicons
were tested by MFOLD http://www.bioinfo.rpi.edu/appli-
cations/mfold/old/dna/ in order to avoid secondary
structures within primer and probe positions.
Direct Sequencing
PCR primers to amplify the CpG island of SNURF pro-
moter were designed by MethPrimer software on line
http://www.urogene.org/methprimer/, which was also
used to predict CpG islands and CpG sites in the
sequence (see Table 1). The amplification of bisulfited-
modified DNA was performed using FastStartTaq™ poly-
merase (Roche, Milan), with the following conditions:
95°C for 4 min, followed by 40 three steps cycles at 95°
C for 30 sec, 60°C for 30 sec and at 72°C for 30 sec.
The PCR products were separated on 3% SeaKem® LE
agarose gels and purified (Agencourt, Beverly, MA), fol-
lowed by sequencing by CEQ2000XL automatic DNA
sequencer (Beckman Coulter,F u l l e r t o n ,C A ) .T h ep r e -
s e n c eo fac y t o s i n er e s i d u ea f t e rb i s u l f i t et r e a t m e n t
shows that the cytosine residue was protected by methy-
lation from bisulfite modification (Fig. 2).
Figure 1 CpG island of SNURF promoter. The upper lane identifies the exact sequence before bisulfite modification. The bottom lane
represents the bisulfite treated methylated forward sequence where all C’s are changed to T’s, except for those followed by a G. Primer
sequences are underlined by >. The internal probe covers two consecutive CpGs (marked as +).
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159 patients (M:F 99:60, median age: 57 years, range
25-77 years) met the inclusion criteria. TMZ concurrent
with and adjuvant to RT was administered in 145
patients (91.2%). MGMT promoter was found methy-
lated by nested MS-PCR in 69 samples (43.39%), and
unmethylated in 90 samples (56.60%), and was found
methylated by MS-qLNAPCR in 70 patients (44.02%),
and unmethylated in 89 samples (55.97%). Concordance
between the two assays was found in 158 of 159 samples
(99.4%). The only patient discordant was found
unmethylated by nested MS-PCR and showed methyla-
tion in less than 1% of cells by MS-qLNAPCR (ratio
between mMGMT/uMGMT = 0.0008).
We tested in parallel two sets of primers specific for
mMGMT and uMGMT with and without LNA modifi-
cations for PCR efficiency in the MS-qLNAPCR assay.
LNA modified primers for mMGMT showed higher
PCR efficiency (slope: -3.271; efficiency: 102%, see
Fig. 3) than unmodified primers (slope: -4.339; effi-
ciency: 69% see Fig. 4). The analytical detection limit of
0.01% was reached only for LNA modified primers,
while conventional primers showed a detection limit of
0.1%. The analytical detection limit (sensitivity limit) of
the MS-qLNAPCR assay was determined using the
Figure 2 Direct Sequencing of SNURF promoter.D i r e c t
sequencing after bisulfite modification of two CpGs of SNURF for
case BF215. The arrows indicates the simultaneous presence of C/T
(C: black peak; T: blue peak) due to a balanced amount of
methylated and unmethylated cytosine in the CpGs amplified with
our primer set.
Figure 3 Standard curves for MS-qLNAPCR with LNA primers. MS-qLNAPCR standard curves with serial dilution mixtures of SssI-treated DNA:
untreated DNA (100%, 50%, 10%, 1%, 0.1%, 0.01%, 0.001%; each containing 1.5 μg of template DNA) for LNA primers specific for mMGMT. LNA
modified primers for mMGMT show higher PCR efficiency (slope: -3.271; efficiency: 102%) than conventional primers (slope: -4.339; efficiency:
69%, see Fig.4). The analytical detection limit of 0.01% is reached only with LNA primers.
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SssI-treated DNA: untreated DNA (100%, 50%, 10%, 1%,
0.1% 0.01% each containing 1.5 μg of template DNA).
1.5 μg of SssI treated DNA (hypothetically fully methy-
lated DNA) maintained a small amount of unmethylated
DNA for MGMT promoter (0.00079%). By this protocol
a sensitivity of 0.01% methylated alleles was detected and
confirmed by the 24 replicates with a 95% cut-off value,
according to common diagnostic practices [38].
The specificity of the assays was assessed by purifica-
tion and analysis of a series of DNA from whole blood
of 24 healthy donors without detecting any methylated
allele for MS-qLNAPCR. On the contrary we detected
two methylated cases by nested MS-PCR.
The total failure rate of unmethylated allele PCR was
0%. Inhibitors were not observed due to the high effi-
ciency of DNA extraction and bisulfite treated DNA
purification.
During the evaluation tests, 12 replicates of dilution
mixture of 0.01% SssI-treated DNA in a background of
1.5 μg of untreated DNA were evaluated with no false
negative results.
Evaluating SNURF data from 24 healthy blood donors,
we found a mean difference between methylated and
unmethylated SNURF alleles of 0.001 (SD = 0.81); the nor-
mality range was therefore estimated as [-1.57, +1.59].
Values outside the SNURF normality range were detected
in 14 out of 159 GBM (8.8%; see the Additional file 1 for
details). In these cases we could not calculate the methy-
lated/unmethylated MGMT allele ratio because the
requirement for using SNURF as a reference is that methy-
lated and unmethylated SNURF alleles are at a ratio of 1:1.
The SNURF promoter of the 14 cases with Ct ratio
[(mSNURF -u SNURF)] outside the normality range
was sequenced to verify whether they showed the
simultaneous presence of both methylated and
unmethylated cytosine in each of the CpGs interro-
gated by the primers and beacon probes. Every speci-
men showed the presence of both methylated and
unmethylated cytosine in the CpGs (see Fig. 1 and
Fig. 2), demonstrating that the Ct ratios outside nor-
malcy are not due to primer mismatch and different
PCR efficiency for the methylated and unmethylated
alleles. Of the 14 GBMs with Ct ratio outside the nor-
mality range only five among methylated cases had
MGMT methylation and the ΔCt of SNURF had some
impact on the final calculation for the mMGMT/
uMGMT ratio in only one of 70 cases (1.42%, sample
Figure 4 Standard curves for MS-qPCR with conventional primers. MS-qPCR standard curves with serial dilution mixtures of SssI-treated
DNA:untreated DNA (100%, 50%, 10%, 1%, 0.1%, 0.01%, 0.001%; each containing 1.5 μg of template DNA) for conventional primers[35] specific
for mMGMT. Conventional primers for mMGMT show lower PCR efficiency (slope: -4.339; efficiency: 69%) than LNA modified primers (see Fig.3).
The analytical detection limit with the use of conventional primers was 0.1%.
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showing both methylated and unmehtylated cytosines
for each of the CpGs tested (see Fig. 2). This indicates
that the BF215 ratio of Ct [(mSNURF -u SNURF)] is
not due to primer/probe mismatch but may be the
result of a partial loss of imprinting (LOI) of the
maternal allele (see Additional file 1 for details).
With our MS-qLNAPCR protocol we identified 70 of
159 MGMT methylated cases (44.0%). In addition,
MS-qLNAPCR allows a fine discrimination of the
relative amounts of methylated vs. unmethylated
MGMT in a given case (see Fig. 5). Quantitative analysis
showed a bimodal distribution of ratio values between
methylated and unmethylated MGMT alleles, with two
prevalent groups with ratios between 0.001-0.33 and
0.67-1, respectively (see Fig. 6). This bimodal distribu-
tion is similar to that found by Vlassenbroeck et al. [27].
Survival
Median overall survival of the 159 patients was of 24
months (95%CI: 21 - 27), being 20 months and 36 (95%
CI: 17.7 - 54.3) months, in patients with MGMT
unmethylated and methylated tumors by nested
MS-PCR, respectively (log-rank test, p = 0.004). Consid-
ering MGMT methylation data provided by our
MS-qLNAPCR protocol as a binary variable, overall
survival was statistically different between patients with
GBM samples harboring MGMT promoter unmethy-
lated and other patients with any percentage of MGMT
methylation (log-rank test, p = 0.003, Fig. 7). This differ-
ence was retained using other cut off values for MGMT
methylation rate (i.e. 10% and 20% of methylated cells),
while the difference was lost when 50% of MGMT
methylated cells was used as cut-off. Overall survival
significantly correlated with MGMT promoter methyla-
tion status determined either by nested MS-PCR
(p = 0.021) or MS-qLNAPCR (p = 0.025) even after the
14 patients that received RT followed by adjuvant TMZ
were excluded.
Discussion
Given the key roles of cytosine methylation, there has
been a wide interest in the development of procedures
for DNA methylation analyses [15]. The prognostic sig-
nificance of MGMT promoter methylation has been
shown in two chemoradiotherapy clinical trials; first in a
phase II study testing concomitant and adjuvant temo-
zolomide and radiation [39] and subsequently in
EORTC 26981/22981 & NCIC CE.3 [14]. In the later
study, MGMT promoter methylation was an indepen-
dent favourable prognostic factor and patients whose
tumour contained a methylated MGMT promoter had
median survival of 21.7 months and 2-year survival of
46%, when treated with temozolomide and radiotherapy.
These studies suggest that determination of MGMT
methylation status maybe an important factor in deter-
mining which glioblastoma patients should receive che-
moradiotherapy [40], but its prognostic significance in
the routine clinical setting is not clearly established.
Methylation-specific PCR (MSP) is widely used to test
MGMT promoter methylation; however, in EORTC
26981/22981 & NCIC CE.3 Hegi et al. [14] only
achieved methylation data for 67% of samples analysed,
representing 36% of cases.
Sensitive, accurate, high-throughput and cost-effective
methods should give a better definition of the role and
control of this epigenetic modification, especially in can-
cer. Many different experimental approaches have been
developed to allow either global large-scale or specific
analyses [2,3,6,15-23]. The most popular approaches rely
on bisulfite treatment of DNA [41]. This treatment is
performed in such a way that, while cytosine is quantita-
tively deaminated to uracil, 5-methyl cytosine remains
unmodified, thus allowing identification of the cytosine
methylation status following PCR amplification. There
Figure 5 A representative MS-qLNAPCR plot. A representative
MS-qLNAPCR plot (GBM case BF240) showing an MGMT methylated
ratio value of 0.46.
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sequence detection methods used, which achieve diverse
levels of performance and adequacy. The quantitative
analysis of the cytosine methylation levels at several inde-
pendent proximal positions can be achieved using Pyrose-
quencing analysis of PCR products amplified in a
methylation-independent manner [18,41]. This procedure
is not particularly sensitive and does not perform well
with neoplastic populations that represents <10% of the
sample, which limits its usefulness in the analysis of het-
erogeneous pathological samples and of early events in
epigenetic reprogramming. MS-PCR [42] is the most
widely used assay for the detection of hypermethylation
in CpG islands. It relies on the selective PCR amplifica-
tion of sequences corresponding to either unmethylated
or methylated DNA using primers that anneal specifically
with either one of the DNA species. For methylation-
specific annealing, each primer must contain sequences
corresponding to at least two CpG dinucleotides. This
method allows sensitive detection of particular methyla-
tion patterns and is currently used for the analysis of
pathological samples.
MS-PCR has been adapted to fluorescence-based real-
time PCR technology, thus allowing for both quantitative
and high-throughput sample analysis [17,18,27,28,42,43].
Eads CA et al. introduced quantitative methylation
sensitive PCR based on TaqMan® chemistry [24], deter-
mining the relative amounts of a particular methylation
pattern with quantitative accuracy. Hattermann K et al.
[44] described a method combining methylation specific
a n dS Y B Rg r e e nb a s e dq u a n t i t a t i v eP C Ra l l o w i n gt h e
quantification of fully methylated and fully unmethylated
MGMT DNA species. Values were related to standard
curves, corrected for DNA input by an internal calibra-
tor, and calculated in relation to methylated and
unmethylated control DNAs as a percentage share [44].
Smith E et al. [26] described an elegant and cost effec-
tive quantitative methylation sensitive PCR based on
Figure 6 Bimodal distribution of methylated and unmethylated alleles. Normalized ratio value groups between methylated and
unmethylated alleles of the 70 MGMT methylated GBMs identified with our MS-qLNAPCR protocol. There is a bimodal distribution of cases with
two prevalent groups showing ratio values between 0.001-0.33 and 0.67-1, respectively.
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bisulfite modified DNA in a real-time thermocycler.
Vlassenbroeck I et al. [27] validated a direct quantitative
methylation sensitive PCR assay based on SYBRGreen
detection chemistry, which quantifies the copy number
of the methylated MGMT promoter after normalization
of Ct values with the ACTB reference gene. To the best
of our knowledge, we are the first to describe and vali-
date a method to quantitate DNA methylation using
LNA modified primers and an imprinted gene as a
reference, instead of a methylation independent calibra-
tor such as ACTB [27]. In our opinion ACTB does not
represent the best reference gene for normalization
because it is located at 7p15-p12, a chromosomal site
subject to copy number variations in gliomas [45,46],
and because it is close EGFR (located at 7p12) that is
amplified in about 40% of GBMs [47]. We use of an
imprinted gene (SNURF) as an internal control, because
it may check the efficiency of the assay from DNA puri-
fication, through bisulfite treatment to PCR. Addition-
ally it should be used as a reference because mSNURF
and uSNURF mimic the biallelic MGMT status. In fact,
in normal cells the maternal allele of SNURF is methy-
lated at the promoter locus, while the paternal allele of
the same gene is usually unmethylated and expressed
[30]. This condition is thus similar to a tumor popula-
tion of cells in which the MGMT is methylated at one
of the two alleles. In order to consider SNURF as an
ideal reference, the ratio between methylated and
unmethylated SNURF alleles might not be disturbed by
copy number changes, or by loss of imprinting, both of
which are common in cancer. However, several refer-
ences demonstrate that SNURF, which has been mapped
at 15q12, is hardly ever altered in gliomas [45,48-51].
These data were confirmed by our study because the
methylated and unmethylated SNURF ΔCt of the most
part of cases (91.2%) was nearly always very close to 0.
The SNURF methylation values outside the normality
r a n g ei n1 4o ft h e1 5 9G B M s( 8 . 8 % )m a yb ed u et oa
distinct CpG methylation pattern among tumor cell
population, to partial loss of one allele (LOI: loss of
imprinting), or to a methylation machinery disorder that
methylates the paternal allele (GOI: gain of imprinting).
The requirement for using SNURF as a reference is that
methylated and unmethylated SNURF alleles are at a
ratio of 1:1, and in our series in only one of these 14
cases did the ΔCt of SNURF h a v ean e g a t i v ei m p a c to n
the final calculation for the mMGMT/uMGMT ratio. In
these circumstances we avoid using SNURF as a refer-
ence loosing relative quantification data.
By sequencing the SNURF promoter of this abnormal
case (BF215, Fig. 2), we found a balanced ratio between
methylated and unmethylated cytosine in CpG interro-
gated loci. These data demonstrate for this case that the
ΔCt found to be outside the normality range is not due
to primer/probe mismatch but may be the result of a
partial LOI of the maternal allele.
LNA based PCR has been widely used to achieve high
specificity for the detection of single nucleotide poly-
morphism (SNP). LNA primers show very accurate mis-
match discrimination in comparison with conventional
DNA primers at all 3’-terminal positions [37]. Moreover,
they offer greater sensitivity with respect to TaqMan
based SNP detection due to the fact that in allele speci-
fic PCR for SNP detection two PCR amplify selectively
each allele. On the other hand, in case of TaqMan tech-
nology a single PCR with flanking primers will amplify
in parallel both alleles. If one allele is poorly represented
(e.g. in samples with low density of tumor cells in a
background of normal cells) the TaqMan probe may fail
to detect or underestimate the less represented allele.
Because of these reasons we have taken advantage of
3’-LNA modified primers and molecular beacon detec-
tion chemistry [52,53] to developed a direct methylation
sensitive quantitative PCR (MS-qLNAPCR) assay.
Although allele specific assays provide an elegant
method to discriminate between alleles, quantification of
the variants is not attainable because of the intrinsic
endpoint detection by conventional PCR. This limitation
is fully addressed using real-time qPCR methods [54],
whereby PCR product accumulation is monitored at
each PCR cycle by means of fluorescent detection using
molecular beacon chemistry. Unlike previously described
methylation sensitive quantitative PCR protocols [27,28],
our new MS-qLNAPCR approach is based on two
Figure 7 Kaplan-Meier survival curves. Survival curves of GBM
patients with methylated MGMT promoter (thick line) and
unmethylated MGMT promoter (thin line) determined by
MS-qLNAPCR. Patients with tumors with unmethylated MGMT
promoter have lower overall survival (Log rank test p = 0.003).
Morandi et al. BMC Cancer 2010, 10:48
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methylated allele and the other one recognizing the
unmethylated allele.
These probes were designed to span two CpGs in
order to obtain high specificity compared with previous
MS-PCR or MS-qPCR methods with SYBRGreen detec-
tion, with high discriminatory power between the
methylated and unmethylated MGMT alleles even with
DNA extracted from FFPE samples. Variation of stan-
dard curves run in parallel with tumor samples in each
batch of cases were small and acceptable, indicating
optimal reproducibility. We found our MS-qLNAPCR
protocol particularly reliable when dealing with large
amounts of input DNA since it avoids false positive
results [37].
To limit experimental variation we chose to utilize the
same primers used by Hegi et al. which have been clini-
cally validated on a large number of samples [14,19,35].
We modified the primers only to insert the LNA nucleo-
tides to improve the assay and demonstrated that our
LNA modified primers show optimal PCR efficiency and
high sensitivity, better than that of large clinical studies
[14]. These have so far largely used nested MS-PCR.
MS-qLNAPCR offers many advantages compared with
nested MS-PCR, including ease of interpretation com-
pared with gel-based methods where weak bands are
often difficult to interpreted, quantitative results, a one
step procedure that saves time and reduces contamina-
tion risk, a broad dynamic range with reproducible
results with both high and very low input DNA amounts.
Low DNA amounts could still be processed also because
the use of the EpiTect Bisulfite kit reduced the intrinsic
DNA fragmentation during the bisulfite treatment. The
advantages of our MS-qLNAPCR protocol make it thus
ideal for high throughput analysis, when large numbers
of clinical samples need to studied.
Vlassenbroeck I et al. [27] using MS-qPCR have
shown that the amount of MGMT promoter methyla-
tion in GBMs is variable, with a bimodal distribution of
cases. With MS-qLNAPCR we have fully confirmed
their data. In addition we demonstrate that epigenetic
silencing of MGMT is associated with response to temo-
zolomide-chemotherapy even when the amount of the
methylated MGMT allele is low. This is very important
for the clinical implications of a molecular diagnosis of
MGMT promoter methylation in GBMs. Since low
levels of MGMT promoter methylation retain a predic-
tive value, even weak methylation signals should be
reported. The biological explanation of the phenomenon
is unclear, but it should be kept in mind that, next to
MGMT, other factors may be involved in temozolomide
response (e.g. the high activity of poly-ADP ribose poly-
merase and base excision repair machinery [55,56]).
Conclusions
We report and validate clinically, a novel, accurate,
robust, and cost effective MS-qLNAPCR protocol for
the detection and quantification of methylated MGMT
alleles. This protocol is the only quantitative method
validated to date from both technical and clinical stand-
points for GBM samples. Using MS-qLNAPCR we
demonstrate that even low levels of MGMT promoter
methylation have to be taken into account to predict
response to temozolomide-chemotherapy.
Additional file 1: MS-qLNAPCR and nested PCR data comparison.
this file includes MS-qLNAPCR and nested PCR data for each of the 159
cases. GBM = glioblastoma; Nested-PCR: methylation status obtained by
nested PCR; MS-qLNAPCR: methylation status obtained by MS-qLNAPCR.
Met/Unmet Ratio: relative DNA copy number ratio between methylated
and UnMethylated allele calculated from the formula described in
Materials and methods; Ct [(mSNURF - uSNURF)]: delta Ct between
SNURF methylated allele and SNURF UnMethylated allele.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2407-10-
48-S1.XLS]
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